Nurix Therapeutics
NRIX----
Nurix Therapeutics (NRIX)
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibod...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Nurix Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 23, 2026Price forecast
$33.0041.15%
Forecast & RatingStrong buy
15analysts
- Strong buy60.00%
- Buy33.33%
- Hold6.67%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 21 at 03:01 PM
Nurix Therapeutics, Roche partner to co-develop BTK degrader bexobrutideg in deal worth up to $2.3 billion
- TradingView · Jul 16 at 11:20 PM
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.87, Implies 42% Upside
- TradingView · Jul 10 at 05:20 PM
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.5, Implies 32% Upside
- TradingView · Jul 10 at 11:20 AM
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.25, Implies 31% Upside
- TradingView · Jul 10 at 02:20 AM
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.12, Implies 30% Upside
- Market Beat · Jul 9 at 03:26 PM
Nurix Therapeutics (NASDAQ:NRIX) Releases Quarterly Earnings Results
